Fate Therapeutics Q1 operating loss narrows, cash runway extended into 2028

Overview

• Biopharmaceutical firm's Q1 collaboration revenue declined yr/yr

• Q1 operating expenses fell 20% from prior year, extending cash runway into 2028

• Company advanced clinical pipeline, including new regulatory milestones and upcoming Phase 2 trial

Outlook

• Company expects to initiate Phase 2 RECLAIM-LN trial of FT819 in 2nd half of 2026

• Fate Therapeutics plans to submit IND and start Phase 1 FT839 autoimmune study in 2nd half 2026

• Company says operating runway extends into 2028

Result Drivers

• OPERATING EXPENSE REDUCTION - Co said a 20% yr/yr decrease in operating expenses extended its cash runway into 2028

• COLLABORATION REVENUE - Q1 revenue was derived from preclinical development activities under collaboration with Ono Pharmaceutical

Company press release: ID:nGNX8K3mMq

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Fate Therapeutics Inc is $6.00, about 166.7% above its May 12 closing price of $2.25

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.